The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
A Crosstalk Between Myeloma Cells and Marrow Stromal Cells Stimulates Production of DKK1 and Interleukin-6: A Potential Role in the Development of Lytic Bone Disease and Tumor Progression in Multiple Myeloma
Abstract
Multiple myeloma (MM) is a malignancy of antibody-secreting plasma cells. B-cell plasmacytomas stimulate bone resorption and angiogenesis, resulting in osteolytic lesions in the skeleton which persist upon successful treatment of the malignancy with chemotherapy. We found that an interaction between MM cells and mesenchymal stem cells (MSCs) from bone marrow stroma results in the formation and persistence of osteolytic bone lesions. It is known that MM cells activate osteoclast activity and secrete high levels of the Wnt inhibitor, Dickkopf-1, which prevents MSCs from differentiating into osteoblasts. We show that the Wnt signaling activator 6-bromoindirubin-3′-monoxime (BIO) releases MSCs from the osteoinhibitory effects of Dickkopf-1, whereas LiCl treatment does not. Additionally, we show that the >5-kDa fraction of MSC-conditioned medium promotes the proliferation of Dickkopf-1-secreting MM cells and that an interleukin-6 (IL-6)-neutralizing antibody blocks this effect. IL-6 expression levels were higher in undifferentiated MSCs than in MSCs treated with osteogenic medium, remained high in the presence of Dkk1, and were reduced by BIO treatment. Therefore, BIO treatment reduces the MSC-stimulated proliferation of MM cells and may enable MSCs to repair existing osteolytic lesions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
Sato, N., Meijer, L., Skaltsounis, L., Greengard, P., & Brivanlou, A. H. (2004) · Nature Medicine · doi:10.1038/nm979 · Cited by 2,109
Gregory, C. A., Grady Gunn, W., Peister, A., & Prockop, D. J. (2004) · Analytical Biochemistry · doi:10.1016/j.ab.2004.02.002 · Cited by 1,561
Self-citationCanonical wnt signaling in differentiated osteoblasts controls osteoclast differentiation.
Glass, D. A., Bialek, P., Ahn, J. D., Starbuck, M., Patel, M. S., Clevers, H., Taketo, M. M., Long, F., McMahon, A. P., Lang, R. A., et al. (2005) · Developmental Cell · doi:10.1016/j.devcel.2005.02.017 · Cited by 1,558
Tian, E., Zhan, F., Walker, R., Rasmussen, E., Ma, Y., Barlogie, B., & Shaughnessy, J. D. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030847 · Cited by 1,503
The specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369
Dankbar, B., Padró, T., Leo, R., Feldmann, B., Kropff, M., Mesters, R. M., Serve, H., Berdel, W. E., & Kienast, J. (2000) · Blood · doi:10.1182/blood.v95.8.2630 · Cited by 566
Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes
Jope, R. S. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00206-2 · Cited by 500
Bataille, R., Jourdan, M., Zhang, X. G., & Klein, B. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114392 · Cited by 479
Barlogie, B., Shaughnessy, J., Tricot, G., Jacobson, J., Zangari, M., Anaissie, E., Walker, R., & Crowley, J. (2004) · Blood · doi:10.1182/blood-2003-04-1045 · Cited by 464
Cited by
Bartosh, T. J., Ylöstalo, J. H., Mohammadipoor, A., Bazhanov, N., Coble, K., Claypool, K., Lee, R. H., Choi, H., & Prockop, D. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008117107 · Cited by 958
Self-citationUnderstanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932
Choi, H., Lee, R. H., Bazhanov, N., Oh, J. Y., & Prockop, D. J. (2011) · Blood · doi:10.1182/blood-2010-12-327353 · Cited by 637
Self-citationBreast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks
Liu, S., Ginestier, C., Ou, S. J., Clouthier, S. G., Patel, S. H., Monville, F., Korkaya, H., Heath, A., Dutcher, J., Kleer, C. G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-0538 · Cited by 611
Prockop, D. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.62 · Cited by 577
Self-citationThe microenvironment in mature B-cell malignancies: a target for new treatment strategies
Burger, J. A., Ghia, P., Rosenwald, A., & Caligaris-Cappio, F. (2009) · Blood · doi:10.1182/blood-2009-06-225326 · Cited by 577
Raffaghello, L., Bianchi, G., Bertolotto, M., Montecucco, F., Busca, A., Dallegri, F., Ottonello, L., & Pistoia, V. (2008) · Stem Cells · doi:10.1634/stemcells.2007-0416 · Cited by 517
The role of Dickkopf-1 in bone development, homeostasis, and disease
Pinzone, J. J., Hall, B. M., Thudi, N. K., Vonau, M., Qiang, Y.-W., Rosol, T. J., & Shaughnessy, J. D. (2009) · Blood · doi:10.1182/blood-2008-03-145169 · Cited by 408
Sclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases
Ke, H. Z., Richards, W. G., Li, X., & Ominsky, M. S. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1060 · Cited by 402
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
Fulciniti, M., Tassone, P., Hideshima, T., Vallet, S., Nanjappa, P., Ettenberg, S. A., Shen, Z., Patel, N., Tai, Y.-T., Chauhan, D., et al. (2009) · Blood · doi:10.1182/blood-2008-11-191577 · Cited by 399
Ohtaki, H., Ylostalo, J. H., Foraker, J. E., Robinson, A. P., Reger, R. L., Shioda, S., & Prockop, D. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803670105 · Cited by 387
Self-citationInterleukin-6 in bone metastasis and cancer progression
Ara, T., & DeClerck, Y. A. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.026 · Cited by 379
Pathogenesis of bone disease in multiple myeloma: from bench to bedside
Terpos, E., Ntanasis-Stathopoulos, I., Gavriatopoulou, M., & Dimopoulos, M. A. (2018) · Blood Cancer Journal · doi:10.1038/s41408-017-0037-4 · Cited by 354
Mesenchymal stromal cell ‘licensing’: a multistep process
Krampera, M. (2011) · Leukemia · doi:10.1038/leu.2011.108 · Cited by 358
Bone marrow mesenchymal stem cells are abnormal in multiple myeloma
Corre, J., Mahtouk, K., Attal, M., Gadelorge, M., Huynh, A., Fleury-Cappellesso, S., Danho, C., Laharrague, P., Klein, B., Rème, T., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404621 · Cited by 328
Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma
Harmer, D., Falank, C., & Reagan, M. R. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00788 · Cited by 307
Mesenchymal Stromal Cell Therapeutic Delivery: Translational Challenges to Clinical Application
Caplan, H., Olson, S. D., Kumar, A., George, M., Prabhakara, K. S., Wenzel, P., Bedi, S., Toledano-Furman, N. E., Triolo, F., Kamhieh-Milz, J., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01645 · Cited by 306
Self-citationMultiple myeloma bone disease: pathophysiology of osteoblast inhibition
Giuliani, N., Rizzoli, V., & Roodman, G. D. (2006) · Blood · doi:10.1182/blood-2006-05-026112 · Cited by 302
Bernardo, M. E., Avanzini, M. A., Perotti, C., Cometa, A. M., Moretta, A., Lenta, E., Del Fante, C., Novara, F., de Silvestri, A., Amendola, G., et al. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.20911 · Cited by 277
Evolving paradigms for repair of tissues by adult stem/progenitor cells (MSCs)
Prockop, D. J., Kota, D. J., Bazhanov, N., & Reger, R. L. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01151.x · Cited by 260
Self-citationAnderson, K. C., & Carrasco, R. D. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130249 · Cited by 258
Concise Review: Adult Multipotent Stromal Cells and Cancer: Risk or Benefit?
Lazennec, G., & Jorgensen, C. (2008) · Stem Cells · doi:10.1634/stemcells.2007-1006 · Cited by 255
Roddy, G. W., Oh, J. Y., Lee, R. H., Bartosh, T. J., Ylostalo, J., Coble, K., Rosa, R. H., & Prockop, D. J. (2011) · Stem Cells · doi:10.1002/stem.708 · Cited by 254
Self-citationMesenchymal stem cell‐based therapy: a new paradigm in regenerative medicine
Satija, N. K., Singh, V. K., Verma, Y. K., Gupta, P., Sharma, S., Afrin, F., Sharma, M., Sharma, P., Tripathi, R. P., & Gurudutta, G. U. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00857.x · Cited by 252
Mesenchymal Stromal Cells Promote Tumor Growth through the Enhancement of Neovascularization
Suzuki, K., Sun, R., Origuchi, M., Kanehira, M., Takahata, T., Itoh, J., Umezawa, A., Kijima, H., Fukuda, S., & Saijo, Y. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.00157 · Cited by 244
Therapeutic potential of mesenchymal stromal cells in a mouse breast cancer metastasis model
Sun, B., Roh, K.-H., Park, J.-R., Lee, S.-R., Park, S.-B., Jung, J.-W., Kang, S.-K., Lee, Y.-S., & Kang, K.-S. (2009) · Cytotherapy · doi:10.1080/14653240902807026 · Cited by 214
Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options
van Andel, H., Kocemba, K. A., Spaargaren, M., & Pals, S. T. (2019) · Leukemia · doi:10.1038/s41375-019-0404-1 · Cited by 188
Arnulf, B., Lecourt, S., Soulier, J., Ternaux, B., Lacassagne, M.-N., Crinquette, A., Dessoly, J., Sciaini, A.-K., Benbunan, M., Chomienne, C., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404466 · Cited by 190
Bjorklund, C. C., Ma, W., Wang, Z.-Q., Davis, R. E., Kuhn, D. J., Kornblau, S. M., Wang, M., Shah, J. J., & Orlowski, R. Z. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.180208 · Cited by 130
Evidences of Early Senescence in Multiple Myeloma Bone Marrow Mesenchymal Stromal Cells
André, T., Meuleman, N., Stamatopoulos, B., De Bruyn, C., Pieters, K., Bron, D., & Lagneaux, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059756 · Cited by 107
Xu, S., Menu, E., Becker, A. D., Van Camp, B., Vanderkerken, K., & Van Riet, I. (2012) · Stem Cells · doi:10.1002/stem.787 · Cited by 103
Hospicells (ascites-derived stromal cells) promote tumorigenicity and angiogenesis
Pasquet, M., Golzio, M., Mery, E., Rafii, A., Benabbou, N., Mirshahi, P., Hennebelle, I., Bourin, P., Allal, B., Teissie, J., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.24886 · Cited by 82
Wnt modulation in bone healing
Schupbach, D., Comeau-Gauthier, M., Harvey, E., & Merle, G. (2020) · Bone · doi:10.1016/j.bone.2020.115491 · Cited by 60
Mesenchymal stem cells inhibit multiple myeloma cells via the Fas/Fas ligand pathway
Atsuta, I., Liu, S., Miura, Y., Akiyama, K., Chen, C., An, Y., Shi, S., & Chen, F.-M. (2013) · Stem Cell Research & Therapy · doi:10.1186/scrt322 · Cited by 57
ZHANG, P., DONG, L., YAN, K., LONG, H., YANG, T.-T., DONG, M.-Q., ZHOU, Y., FAN, Q.-Y., & MA, B.-A. (2013) · Oncology Reports · doi:10.3892/or.2013.2619 · Cited by 54
Bone marrow inflammation in haematological malignancies
de Jong, M. M. E., Chen, L., Raaijmakers, M. H. G. P., & Cupedo, T. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01003-x · Cited by 54
Maiso, P., Mogollón, P., Ocio, E. M., & Garayoa, M. (2021) · Cancers · doi:10.3390/cancers13112542 · Cited by 48
Cytokine-Mediated Dysregulation of Signaling Pathways in the Pathogenesis of Multiple Myeloma
Akhtar, S., Ali, T. A., Faiyaz, A., Khan, O. S., Raza, S. S., Kulinski, M., Omri, H. E., Bhat, A. A., & Uddin, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145002 · Cited by 44
Kanehira, M., Fujiwara, T., Nakajima, S., Okitsu, Y., Onishi, Y., Fukuhara, N., Ichinohasama, R., Okada, Y., & Harigae, H. (2017) · Stem Cells · doi:10.1002/stem.2499 · Cited by 42
García-Sánchez, D., González-González, A., Alfonso-Fernández, A., Del Dujo-Gutiérrez, M., & Pérez-Campo, F. M. (2023) · World Journal of Stem Cells · doi:10.4252/wjsc.v15.i5.421 · Cited by 32
Non-Coding RNAs in Multiple Myeloma Bone Disease Pathophysiology
Raimondi, L., De Luca, A., Giavaresi, G., Raimondo, S., Gallo, A., Taiana, E., Alessandro, R., Rossi, M., Neri, A., Viglietto, G., et al. (2020) · Non-Coding RNA · doi:10.3390/ncrna6030037 · Cited by 16
Metadata
- Authors
- Gunn, W. G., Conley, A., Deininger, L., Olson, S. D., Prockop, D. J., & Gregory, C. A.
- Venue
- Stem Cells
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-04-01
- Volume
- 24
- Issue
- 4
- Pages
- 986-991
- ISSN
- 1066-5099 (ISSN-L)
- 1549-4918
- OpenAlex
- W2031812779
- Cited by
- 261
- References
- 28
- FWCI
- 7.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.